Exenatide vs Liraglutide
How they differ
- FDA status, the same for both (FDA-approved). Exenatide: FDA-approved as Byetta, Bydureon and generic exenatide.1,2,3,4,5 Liraglutide: FDA-approved as Victoza, Saxenda and generic versions.6,7,8,9
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Exenatide | Liraglutide |
|---|---|---|
| What it is | A GLP-1 receptor agonist. The label states that its amino acid sequence partly overlaps that of human GLP-1.1 | A GLP-1 receptor agonist. The label describes it as an acylated human GLP-1 receptor agonist with 97% amino acid sequence similarity to natural human GLP-1.6 |
| FDA status | FDA-approved FDA-approved as Byetta, Bydureon and generic exenatide1,2,3,4,5 FDA-approved. Drugs@FDA lists Byetta (first approved April 28, 2005), Bydureon (January 27, 2012), Bydureon BCise (October 20, 2017) and a generic application (November 19, 2024). The cited generic label has no boxed warning.1,2,3,4,5 | FDA-approved FDA-approved as Victoza, Saxenda and generic versions6,7,8,9 FDA-approved. Drugs@FDA lists Victoza (first approved January 25, 2010), Saxenda (December 23, 2014) and generic liraglutide applications, the first approved December 23, 2024. The label carries a boxed warning about thyroid C-cell tumors in rodents.6,7,8,9 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.10 | Not among the six peptides the policy lists.10 |
| FDA compounding safety-risk page | Not addressed in this profile’s sources. | Not addressed in this profile’s sources. |
| Kinds of studies cited |
|
|
| Records collected | 50 ClinicalTrials.gov records and 49 PubMed records collected | 82 ClinicalTrials.gov records and 58 PubMed records collected |
| Area of study | ||
| Latest dated events |
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1Exenatide injection · SPL version 17 · published 2026-06-30 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 2Drugs@FDA application NDA021773 · original submission status AP · 2005-04-28 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 3Drugs@FDA application NDA022200 · original submission status AP · 2012-01-27 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 4Drugs@FDA application NDA209210 · original submission status AP · 2017-10-20 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 5Drugs@FDA application ANDA206697 · original submission status AP · 2024-11-19 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 6Liraglutide injection, solution · SPL version 6 · published 2026-07-14 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 7Drugs@FDA application NDA022341 · original submission status AP · 2010-01-25 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 8Drugs@FDA application NDA206321 · original submission status AP · 2014-12-23 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 9Drugs@FDA application ANDA215503 · original submission status AP · 2024-12-23 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 10HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 11Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL, 2017) · PMID 28910237 ↗
The New England Journal of Medicine · Official source · Source checked November 14, 2026
- 12Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER, 2016) · PMID 27295427 ↗
The New England Journal of Medicine · Official source · Source checked November 14, 2026
- 13Federal Register notice 2026-23141 · published 2026-11-13 · Determination That DIBENZYLINE (Phenoxybenzamine Hydrochloride) Oral Capsule, 10 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗
Federal Register via GovInfo · Official source · Source checked November 14, 2026
- 14FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026
- 15FDA requests removal of suicidal behavior and ideation warning from certain GLP-1 RA labels ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026